A study concluded that a lifestyle of general inactivity might promote accelerated biological aging. The results were based on alterations discovered in DNA parts, affected by inactivity.

Scientists from the King's College London gathered their findings from an experiment involving 2,401 white twins. The experts gathered DNA from the subjects, while observing them based on their physical activity levels, as well as smoking habits and socioeconomic conditions

Researchers at the University of Alabama in Birmingham have identified five genes that prevent nerve cells from dying and causing muscular degeneration similar to what happens in Parkinson's disease.

The development cited in the Early Edition of the "Proceedings of the National Academy of Sciences" on Jan. 8 offers leads to developing drugs to treat the nerve and muscle-wasting disease that afflicts an estimated one million Americans or learn genetic factors which make some people more susceptible to the disease

The U.S. Food and Drug Administration (FDA) has approved for medical use the first DNA-based blood-clotting drug for surgery made by Seattle-based biochemical firm ZymoGenetics Inc.

The FDA approval, which came Thursday, paves way for ZymoGenetics' partner Bayer HealthCare to start marketing the clotting solution Recothrom, which stop small blood vessels from bleeding after surgery and prevent blood loss

In a breakthrough treatment of cancer, researchers in Houston used Carbon nanotubes heated by radio waves to kill cancer cells.

In a paper posted online by the journal Cancer, a team at the University of Texas M.D. Anderson Cancer Center and Rice University reported that the technique destroyed liver cancer tumors in rabbits and caused no side effects

A DNA-based screening test is more efficient at identifying the human papillomavirus (HPV) than the currently used method, the Pap test. The new test, which won't need a screening test as often, could soon replace the 50-year-old Pap in a matter of years, experts say.

In a new study conducted by McGill University in Montreal, both tests were conducted on more than 10,000 women between 30 and 69-years-old. The DNA test detected 94.6 percent of the abnormal growths that can lead to cervical cancer, while the Pap test found only 55.4 percent of the same growths